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At a time when health is being recognized as more than just avoiding death, age and comorbidity are becoming increasingly
important aspects of chronic disease. Systemic Lupus Erythematous (SLE) is probably one of the best paradigms of modern chronic
disease, sitting at the crossroads of numerous somatic health problems, immune activation, depression, pain, and fatigue. One
hundred forty-eight female participants were enrolled in the present study: 50 diagnosed with SLE, 45 with major depressive
disorder (MDD), and 53 age-matched controls. Statistically significant lower scores in quality-of-life dimensions related to physical
impairment were found in SLE. Patients with MDD presented significant levels of pain, reduced physical summary component
(PSC), and general health scores different from healthy controls. Fatigue was reported in 90% of women with SLE and 77.8% of
the MDD patients in contrast with 39.6% in the control group. Significant correlations were seen among fatigue severity, age,
and educational level in SLE. From our own previous work and more recent work on the association of immune activation and
depression, unexplained fatigue in SLE may signify an early sign of immune activation flare-up. The search for cytokine markers
should perhaps be extended to fatigue in SLE.
1. Introduction
Themore recent analysis of the Global Burden of Disease has
identified mental disorders and musculoskeletal diseases as
some of the major contributors to Years Lived in Disability
(YLD) [1]. One consequence of this study that has particularly
interested us has led to the question of how such global find-
ings can be reflected in the care of the individual patient
and the understanding of the complexity of comorbidity in
chronic disease. Although fatigue, anxiety, and depression
crosstalk with the clinical presentation and progression of
Systemic Lupus Erythematosus (SLE), clinicians generally
pay more attention to the somatic health problems posed by
illness [2]. This can be explained in part by present-day
medical education’s emphasis on the biological, genomic, and
statistically significant dimensions of disease.
Studies of SLE patients have shown, however, the impact
of individual elements such as anxiety and depression on the
course of disease as experienced by individual patients and
how, collectively, such elements have an impact on health care
costs [3].
SLE is also a particularly good example of how progress in
the dissection of genes andmolecules involved in autoimmu-
nity continues to be disappointingly reflected in helping the
individual patient [4]. In addition, SLE as a chronic inflam-
matory autoimmune disease with multisystem involvement,
secondary to the production of autoantibodies and to the pro-
duction of Type 1 interferon by innate immune cells [5, 6],
represents a singularly revealing model of the crossroads
that individual clinicians or clinical teams must face to deal
adequately with an individual patient.
Presently, clinical evaluation of disease reliesmostly upon
objective criteria, contemplating clinical features whose sig-
nificance may nevertheless escape the patient. Particular
symptoms such as pain and fatigue can, on the contrary, be
experienced and reported exclusively by the patient, escaping
regular clinical assessment. We would like to identify such
individual burdens as silent burdens of disease.
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Table 1: Sociodemographic characterization.
Total
𝑛 = 148
SLE (1)
𝑛 = 50
Depression (2)
𝑛 = 45
Controls (3)
𝑛 = 53
𝑃 Post hoc analysis
Age (years)a 44.5 (11.6) 44.1 (10.1) 41.7 (13.7) 47.2 (11.8) 0.108c
Education (years)a 10.7 (4.8) 9.1 (3.9) 13.0 (4.2) 10.9 (5.4) 0.001c 2 > 1, 3
Marital statusb
Single 26 (17.6) 8 (16.0) 10 (22.2) 8 (15.1)
Married 101 (68.2) 38 (76.0) 25 (55.6) 38 (71.7)
Divorced 15 (10.1) 2 (4.0) 9 (20.0) 4 (7.5) 0.254d
Widow 4 (2.7) 1 (2.0) 1 (2.2) 2 (3.6)
Common-law marriage 2 (1.4) 1 (2.0) 0 (0.0) 1 (1.9)
Employment statusb
Active 86 (58.1) 15 (30.0) 27 (60.0) 44 (83.0) 0.000d
Nonactive 62 (41.9) 35 (70.0) 18 (40.0) 9 (17.0)
aMean (standard deviation), b𝑛 (%), cANOVA, dChi-square test.
Eventually, the disrupted immunological tolerance seen
in SLE patients results in immune complex deposition that
ends in permanent damage, most frequently affecting the
musculoskeletal, cutaneous, renal, central nervous, and gas-
trointestinal systems [7].The diversity of the resulting clinical
manifestations led to the establishment of consensual, valu-
able, sensitive, and specific diagnostic criteria: the American
College of Rheumatology (ACR) Criteria for Classification of
Systemic Lupus Erythematosus. Although not formally con-
templated in these criteria, fatigue is themost common symp-
tom in SLE, affecting 67% to 90% of the patients, even inmild
disease presentations [8–10]. Patients often describe their
fatigue as debilitating, causing a severe impact on personal,
family, and social functioning [10]. Resulting from a complex
interplay of biological, behavioral, and psychological factors,
fatigue appears to have a privileged association with depres-
sive symptoms, independently of genetic background [11].
Indeed, fatigue cannot be seen as a purely physical sign, as
it is also a common symptom in depressive disorder [12].
Anxiety and depression are highly prevalent among
patients with lupus, thought to represent central nervous sys-
tem involvement [13] or immune dysfunction manifestation
[14, 15], or denoting the emotional burden of the disease [16,
17]. Recently, a link has been established among neurotrans-
mitter dysfunction, immune activation (lymphocyte abnor-
malities and cytokine expression), and major depression [18,
19]. In this paper, we consider fatigue and depression as exam-
ples of silent burdens of disease, in a cross-sectional study of
three groups of participants: patients with SLE, patients with
major depressive disorder, and age- and sex-matched con-
trols.
The principal objective of the work was twofold: to high-
light the importance of single patient derived symptoms over
the course of the disease and to stress the importance of SLE
as a modern model chronic disease as important as cancer, if
not more so. This importance is derived from the multiple
effects resulting from the challenge of crosstalk between the
immunological system and other systems, in the absence of
infection.
2. Study Participants and Methods
One hundred forty-eight female participants were enrolled in
the present study, 50 of whom were patients diagnosed with
SLE, recruited from the rheumatology outpatient clinic of the
Sa˜o Joa˜o Hospital, EPE. All SLE patients fulfilled the ACR
diagnostic criteria. Only adult patients (>18 years old) with-
out diagnosed psychiatric comorbidities were selected. All
patients attended routine visits at the hospital and completed
regular clinic and laboratorial assessments.
Patients with lupus were compared to one group of 53
healthy age-matched subjects and a group of 45 patients with
major depressive disorder (MDD), followed by one of the
authors (mmfb) in her private psychiatric clinic. Psychiatric
patients were diagnosed by a psychiatrist according to the
Diagnostic and Statistical Manual of Mental Disorders
(DSM-IV-TR) [20]. The study was submitted and approved
by the Ethical Committee of the Sa˜o Joa˜o Hospital (EPE).
Participants received oral and written information about the
study’s goals, methods, expected benefits, and discomfort,
afterwhich they gave their oral andwritten informed consent.
The confidentiality and privacy of the collected data were
guaranteed during the data collection and analysis stages
according to the Declaration of Helsinki.
The sociodemographic characterization of the popula-
tions studied is shown in Table 1.
3. Data Collection
Following a cross-sectional approach, psychosocial data were
collected between September 2012 and June 2013. A first con-
tact established the willingness of the patients to participate.
After a first verbal consent was obtained, written informed
consent was mailed and retrieved from all participants before
the study began. Recruited patients and controls were subse-
quently interviewed by phone by a trained interviewer (RF).
The literature corroborates phone interviews as valid and pre-
cise tools for psychological data collection [21–25].
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Participants’ sociodemographic data included age, educa-
tional level, employment status (active/nonactive), and mar-
ital status. Laboratorial and SLE standardized clinical evalu-
ation were obtained exclusively in the SLE patients through
the clinical records.
4. Instruments
4.1. Psychosocial Evaluation. Psychological variables were
obtained through a battery test: the Fatigue Severity Scale
(FSS), the Hospital Anxiety and Depression Scale (HADS),
the Pittsburgh Sleep Quality Index (PSQI), and the Short
Form-36 Health Survey (SF-36v2).
Self-reported fatiguewas evaluated through the short ver-
sion of the FSS [26]. This unidimensional nine-item Likert
scale was designed to assess fatigue in chronic medical and
rheumatologic conditions and is recommended as the instru-
ment of choice for research purposes in studies involving
patients diagnosed with SLE [27]. The Portuguese version of
the FSS used in the present work has been validated for SLE
patients [28].
The FSS demonstrates good internal consistency (Cron-
bach’s 𝛼 = 0.89 in SLE patients), test-retest reliability (0.84),
and construct and discriminative validity and is sensitive to
change. Each question is scored from 1 to 7, and a final score
is obtained from the mean of all scored items. Higher scores
reveal increasing severity of fatigue. Presence of clinical levels
of fatigue was defined by a FSS score >3, as proposed by
Krupp and collaborators [26].Theuse of FSS assessment in an
SLE population by telephone interview has been established
[29].
The Hospital Anxiety and Depression Scale (HADS) [30]
is used to assess depressive and anxiety symptoms.This ques-
tionnaire contains 14 items, scored from 0 to 3, to achieve a
total of 0 to 21. It is divided into two sets of seven questions
aiming to detect, respectively, depressive and anxiety states.
Scores exceeding 8 points indicate possible mood disorder,
and 10 points delimit pathological situations.This instrument
does not contain items focused in physical indicators of psy-
chological distress or somatic complaints, which improves its
sensitivity to anxiety and depression in physically ill individ-
uals. Factor analysis confirmed the bidimensionality of the
scale and the correlation between the anxiety and depression
subscales. Both subscales showed suitable internal consis-
tency (Mean Cronbach’s alpha = 0.83 for HADS-A and 0.82
for HADS-D) [31]. Telephone-administered mode has been
described for the HADS, maintaining similar psychometric
properties [32].
Participants were also screened for sleep quality through
the Pittsburgh Sleep Quality Index (PSQI). A weighted global
score of 0 to 21, reflecting a four-week time interval, is yielded
from the seven components subjectively evaluated: sleep
latency, sleep disturbances, sleep duration, sleep quality, sleep
efficiency, use of sleepmedications, and daytime dysfunction.
This instrument has good psychometric properties, with
high homogeneity, reliability (Cronbach’s alpha = 0.83), and
validity [33, 34]. Poor sleepers are identified by a PSQI score
>5 [33]. When used in a telephone interview, the PSQI
presented an adequate internal consistency and proved to be
a reliable mode for sleep quality assessment [35, 36].
The Short-Form 36 Health Survey Version 2.0 (SF-36v2)
was elected to assess health-related quality of life (HRQoL)
[37]. This scale comprises 36 self-rated questions, reproduc-
ing eight domains: physical functioning (PF), role limitations
due to physical problems (RP), bodily pain (BP), general
health (GH), vitality (VT), social functioning (SF), role limi-
tations due to emotional problems (RE), and mental health
(MH). These domains can be individually evaluated or sum-
marized in the physical (PSC) and mental (MSC) summary
components. A gradual score ranging from 0 to 100 in each
area reflects enhanced quality of life. The SF-36 can be either
self-administered or administered by a trained interviewer,
either in person or by telephone [38, 39]. The SF-36-v2 is
the most widely used questionnaire to assess quality-of-life-
related outcomes in SLE patients, providing the additional
possibility of comparing the obtained results with those of
other healthy or patient populations [40].The Cronbach’s
alpha for studies enrolling SLE patients was recently com-
puted from the available literature (Cronbach’s 𝛼 = 0.71–0.95)
[41].
4.2. Clinical SLE Indexes. Disease activity was estimated with
the Systemic Lupus Erythematosus Disease Activity Index
(SLEDAI) [42]. This physician-rated instrument reports 16
clinical and eight laboratorial descriptors appraised during
the previous 10 or 30 days.The SLEDAI score retrieved during
the last (most recent) patient visit was used. Patients were
grouped into four categories, according to SLEDAI total
score, representing increasing activity of the disease: no activ-
ity (0),mild activity (1–5),moderate activity(6–10),high activ-
ity (11–19), and very high activity (20) [43]. A score of 6 or
more was considered as clinically active disease.
The Systemic Lupus International Collaborating Clin-
ics/American College of Rheumatology (SLICC/ACR) dam-
age index [44] was used to compile irreversible impairment
in all SLE patients. This index reflects accumulated damage
continuously present in a six-month period and targets 12 dis-
tinct organs/systems.
4.3. Laboratory Evaluation. Laboratorial evaluation included
in the patient’s clinical records was used to determine
immune activation, inflammatory status, antibody profile,
and vitamin D quantifications. Immune activation was deter-
mined by autoantibodies detection: antidouble stranded
DNA, nucleosome, Smith, Sjogren SyndromeA, Sjogren Syn-
drome B, histones, cardiolipin (IgG and IgM isotypes), 𝛽2-
glycoprotein I (IgG and IgM isotypes), antiribonucleopro-
teins, and Ribosomal P substance. The C-Reactive Protein
(CRP), inactive C1, C1q, C3c, C4, and CH50 complement
fractions and Erythrocyte Sedimentation Rate (ESR) deter-
minations were also considered. Blood and serological mea-
surements were performed according to standardized meth-
ods in the hospital’s laboratory, and standardized cutoff levels
were established. Only two laboratory tests correlate with
fatigue: CH50 and anti-ds-DNA determinations (data not
shown).
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Table 2: Fatigue assessment.
Total
𝑛 = 148
SLE (1)
𝑛 = 50
Depression (2)
𝑛 = 45
Controls (3)
𝑛 = 53
𝑃 Post hoc analysis
FSS global scorea,b 4.3 (1.7) 5.2 (1.3) 4.5 (1.4) 3.2 (1.8) 0.000d 2, 1 > 3
1.0–7.0 1.6–7.0 1.7–7.0 1.0–10.4
Fatigue severity levelc
Nonclinical 36 (24.3) 5 (10.0) 6 (13.3) 25 (47.2)
0.000eClinical 101 (68.2) 45 (90.0) 35 (77.8) 21 (39.6)
Missing 11 (7.4) 4 (8.9) 7 (13.2)
aMean (standard deviation); bminimum–maximum; c𝑛 (%); dANOVA; eChi-square test.
Table 3: Correlations (Pearson) between fatigue and psychosocial and anthropometric characteristics, quality of life, and sleep quality.
SLE (1)
𝑛 = 50
Depression (2)
𝑛 = 45
Controls (3)
𝑛 = 53
Age (years) 0.489∗∗ −0.061 0.243
Education (years) −0.476∗∗ −0.043 −0.294
HADS
Anxiety 0.542∗∗ 0.202 0.397∗∗
Depression 0.576∗∗ 0.402∗ 0.410∗∗
SF-36
PSC −0.717∗∗ −0.351∗ −0.466∗∗
Physical functioning −0.648∗∗ −0.103 −0.318∗
Role limitations due to physical health problems −0.699∗∗ −0.393∗ −0.302∗
Social functioning −0.354∗ −0.389∗ −0.226
Mental health −0.464∗∗ −0.416∗∗ −0.435∗∗
Role limitations due to emotional problems −0.315∗ −0.249 −0.274
Vitality −0.677∗∗ −0.323∗ −0.660∗∗
Bodily pain −0.563∗∗ −0.450∗∗ −0.287
General health −0.617∗∗ −0.418∗∗ −0.580∗∗
PSQI global score 0.401∗∗ 0.334∗ 0.425∗∗
BMI (kg/m2) 0.135 −0.82 −0.301∗
∗
𝑃 < 0.05, ∗∗𝑃 < 0.01; PSC: Physical summary component; BMI: body mass index.
4.4. Statistical Analysis. Statistical analysis was performed
using the Statistical Package for Social Science 18.0 (SPSS).
A descriptive analysis of the obtained results was per-
formed, and the data were expressed as frequencies (%), min-
imums, maximums, means, and standard deviations.
Analysis of variance (ANOVA) was used to investigate
differences between groups, and Pearson Chi-square test was
conducted for categorical variables. Post-hoc Tukey test
was performed to provide a stratified comparison between
groups, when necessary. For correlation analysis, the Spear-
man’s coefficient was computed. Confidence intervals of 95%
and a significance level of 0.05 were adopted.
5. Results
5.1. Fatigue Assessment: Significant Associations with Age, Psy-
chological Suffering, and Educational Level (Tables 1, 2, and 3).
The sociodemographic characterization of the three groups
showed that all participants presented similar age, with a
mean value of 44.5 years and similarmarital status. Regarding
employment status and education, however, lower scores
were observed in the SLE group, with statistical significance
when compared to depressed and control women (Table 1).
Fatigue was not an exclusive burden of SLE. It was
reported in 90% of women with SLE and 77.8% of the female
MDD patients, in contrast with 39.6% in the control group.
The global score of FSS revealed similar fatigue severity in
SLE andMDDpatients (5.2±1.3 and 4.5±1.4, resp.), which is
significantly higher than the scores found in the control group
(3.2 ± 1.8, 𝑃 = 0.0001) (Table 2).
The result of the search for significant correlations
between fatigue and markers of psychological suffering is
detailed as a correlational analysis in Table 3.
Significant correlations were detected between fatigue
severity, age, and education exclusively in patients with SLE.
Higher fatigue was associated with older age, possibly reflect-
ing the cumulative physical impairment of disease and aging.
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Table 4: Anthropometric characterization, health-related behaviors, and sleep quality.
Total
𝑛 = 148
SLE (1)
𝑛 = 50
Depression (2)
𝑛 = 45
Controls (3)
𝑛 = 53
𝑃 Post hoc analysis
BMI (kg/m2)a 24.9 (5.5) 24.8 (4.1) 25.7 (7.8) 24.3 (4.0) 0.466c
BMI categoriesb
Underweight 7 (4.7) 1 (2.0) 3 (6.7) 3 (5.7)
0.701d
Normal range 85 ( 57.4) 31 (62.0) 24 (53.3) 30 (56.6)
Preobesity 32 (21.6) 13 (26.0) 8 (17.8) 11 (20.8)
Obesity 18 (12.2) 5 (10.0) 8 (17.8) 5 (9.4)
Missing 6 (4.1) 0 (0.0) 2 (4.4) 4 (7.5)
Smoking habitsb
Smokers 34 (23.0) 10 (20.0) 18 (40.0) 6 (11.3) 0.003d
Nonsmokers 114 (77.0) 40 (80.0) 27 (60.0) 47 (88.7)
Alcohol consumptionb
Yes 13 (8.8) 3 (6.0) 2 (4.4) 8 (15.1) 0.124d
No 135 (91.2) 47 (94.0) 43 (95.6) 45 (84.9)
Physical activityb
Yes 63 (42.6) 18 (36.0) 18 (40.0) 27 (50.9) 0.283d
No 85 (57.4) 32 (64.0) 27 (60.0) 26 (49.1)
Sleep
PSQI global scorea 10.3 (3.8) 10.9 (4.0) 11.3 (3.7) 9.0 (3.4) 0.007c 2, 1 > 3
Quality of sleepb
Good sleepers 16 (10.8) 3 (6.0) 3 (6.7) 10 (18.9)
0.140dPoor sleepers 126 (85.1) 46 (92.0) 39 (86.7) 41 (77.4)
Missing 6 (4.1) 1 (2.0) 3 (6.7) 2 (3.8)
aMean (standard deviation), b𝑛 (%), cANOVA, dChi-square test; BMI: body mass index.
Lower education was seen to be related to higher fatigue
scores.
Significant correlations between anxiety and fatigue were
detected in SLE and control population (𝑟 = 0.542 and 𝑟 =
0.397, resp.).
Mental health scores, vitality, and depressive symp-
toms presented significant associations with fatigue severity,
regardless of participant group (Table 3).
In the SLE group of women, education correlated signif-
icantlywith anxiety (HADS-A:𝑟 = 0.313, 𝑃 = 0.027), depres-
sive symptoms (HADS D 𝑟 = 0.452, 𝑃 = 0.001), and bodily
pain (𝑟 = 0.527, 𝑃 < 0.005).
5.2. Weight, Sleep, and Physical Activity (Table 4). In order to
clarify classically reported associations among fatigue, exces-
sive weight, sleep abnormalities, and physical activity, partic-
ipants were subjected to anthropometric, sleep quality, and
health-related behavior evaluations.
In our study, disturbed sleep quality affected the three
groups, although higher global PSQI scores (𝑃 = 0.007), rep-
resenting poorer sleep quality, were detected in SLE and
MDD patients.
The presence of obesity and preobesity was equally dis-
tributed across the studied sample, and BMI scores were sim-
ilar in all the groups. Evaluation of health-related behaviors
revealed that physical activity and alcohol consumption were
similar in the three groups. Smoking habits, on the contrary,
were more prevalent in psychiatric patients (Table 4).
5.3. Fatigue and Quality-of-Life Dimensions: Physical Sum-
mary Components, Pain, and General Health (Table 5).
Fatigue has been extensively associated with poorer health-
related quality of life in SLE patients. Accordingly, we
detected statistically significant lower scores in quality-of-life
dimensions related to physical impairment in SLE patients;
results in physical summary components, bodily pain and
general health were statistically significantly different in the
SLE group when compared to the MDD group and control
subjects. MDD patients, however, presented significant levels
of pain, reduced PSC, and general health scores different from
healthy controls.
Other dimensions expressed in mental summary compo-
nents (social functioning, mental health, and role limitations
due to emotional problems),whileshowing significant impair-
ment in SLE patients, presented lower scores in the MDD
group when compared to the control population (Table 5).
5.4. Fatigue, Anxiety, andDepression (Table 6). Loss of energy
or exhaustion can characterize fatigue and also be regarded
as a depressive symptom. In the present study, measures
of depression were obtained using HADS depression sub-
scale in the three groups of participants, and they revealed
6 Autoimmune Diseases
Table 5: Health-related quality of life.
Total
𝑛 = 148
SLE (1)
𝑛 = 50
Depression (2)
𝑛 = 45
Controls (3)
𝑛 = 53
𝑃
Post hoc
analysis
SF-36
Physical functioninga 71.8 (26.7) 55.8 (30.5) 75.9 (22.2) 84.3 (16.7) 0.000b 1 < 2, 3
Role limitations due to physical health problemsa 62.5 (30.8) 44.5 (32.6) 59.8 (23.5) 81.3 (22.4) 0.000b 1 < 2 < 3
Social functioninga 63.0 (28.6) 61.5 (31.0) 46.6 (22.5) 78.1 (22.5) 0.000b 2 < 1 < 3
Mental healtha 56.8 (22.1) 55.8 (20.2) 43.0 (17.5) 69.3 (20.2) 0.000b 2 < 1 < 3
Role limitations due to emotional problemsa 70.1 (27.9) 68.7 (29.0) 52.4 (22.9) 86.5 (20.5) 0.000b 2 < 1 < 3
Vitalitya 45.6 (22.9) 34.9 (23.1) 39.4 (16.8) 70.0 (18.8) 0.000b 1, 2 < 3
Bodily paina 60.7 (31.6) 43.7 (34.6) 64.5 (26.1) 73.7 (25.5) 0.000b 1 < 2, 3
General healtha 49.8 (23.7) 31.3 (18.5) 56.2 (21.2) 61.9 (19.2) 0.000b 1 < 2, 3
PSCa 0.0 (1.0) −0.8 (0.9) 0.4 (0.7) 0.5 (0.6) 0.000b 1 < 2, 3
MSCa 0.0 (1.0) 0.1 (0.9) −0.8 (0.8) 0.6 (0.8) 0.000b 2 < 3 < 1
aMean (standard deviation); bANOVA; PSC: physical summary component; MSC: mental summary component.
Table 6: Depression and anxiety symptoms.
Total
𝑛 = 148
SLE (1)
𝑛 = 50
Depression (2)
𝑛 = 45
Controls (3)
𝑛 = 53
𝑃 Post hoc analysis
HADS-Da 6.4 (4.5) 6.7 (5.0) 8.4 (4.0) 4.5 (3.5) 0.000b 2, 1 > 3
HADS-Aa 8.8 (4.6) 8.5 (4.8) 11.4 (3.7) 6.8 (4.1) 0.000b 2 > 1, 3
aMean (standard deviation); bANOVA.
Table 7: Correlation (Pearson) between fatigue and disease-related
markers in SLE patients.
FSS
SLEDAI −100
SLICC 0.043
the occurrence of similar depressive symptoms in SLE
patients and MDD patients (6.7 ± 5.0 and 8.4 ± 4.0, resp.),
which are significantly higher than in the normal population.
Anxiety presented higher scores inMDDpatients (11.4±3.7),
which are statistically significantly different from the SLE and
control groups.
5.5. Lack of Correlations between Clinical SLE Evaluation and
Severity of Fatigue (Table 7). Clinical indexes used to assess
disease activity and damage in SLE patients did not present
significant associations with fatigue severity, failing to trans-
late subjective patients’ complaints into clinical standardized
evaluation.
6. Discussion
Thespectacular progress in our understanding of themolecu-
lar and genetic basis of disease is transforming clinical prac-
tice and the nature of patient-physician interaction. Indeed,
distracted by the panoply of biological markers at his/her dis-
posal, the clinician may miss subjective symptoms of rele-
vance to the development of disease. Fatigue, anxiety, and
depression fall in the category of subjective symptoms that
may escape the attention of clinicians and patients. Because
of their impact in the course of a chronic disease such as SLE,
such symptoms will become of increasing clinical and social
value as the concept of health itself changes. As emphasized
by others, “health is about more than avoiding death” [1].
As shownby the results of the present study, some correla-
tions of fatigue, for example, with sleep quality were common
to all groups examined, namely, SLE, MDD, and the control
group. A correlation of fatigue with anxiety was also seen
within the control group.
The presence of obesity and BMI scores was similar in
all groups just as alcohol consumption and physical activity.
Smoking habits weremore prevalent in the psychiatric group.
We would like to highlight two observations made exclu-
sively in SLE: the correlation with age and education and the
correlation with depression (not exclusively seen in SLE).
6.1. Fatigue and Depression. In a recent analysis of fatigue in
monozygotic and dizygotic twins, chronic fatigue and psy-
chological distress were strongly associated without evidence
of genetic covariation, implying, according to the authors,
that the “association is environmental” [11]. In an earlier large
analysis of aWorldHealthOrganization longitudinal study of
fatigue and depression, Skapinakis et al. concluded that unex-
plained fatigue and depression might act as independent
factors of each other [45].
However, Palagini et al., in a review based on the search of
SLE and depression as key-words in several major databases,
concluded that to date, the relationship between depression
and SLE disease activity appears controversial, stressing
the need for identification of SLE-specific biomarkers of
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depression. Methodological limitations are present in the
available literature, and the standardization ofmethodologies
should be considered a high priority in SLE research [46].
In the present cross-sectional study, we confirmed the
existence of a link between fatigue and depression in the
patients studied. From our own previous work [14] and more
recent work on the association of immune activation and
depression, unexplained fatigue may signify an early alert
signal of a flare-up of immune activation [18, 19], and the
search for cytokine markers in SLE [47] should perhaps be
extended to fatigue in SLE.
6.2. Fatigue and Education Level. Comparison of educational
levels can be done only between the SLE and control groups.
The link between education level and fatigue strengthens the
point made by others about the importance of the role
of health professionals, including nurses, in explaining the
disease to patients [48]. Patients with lower education levels
challenge clinicians and other health professionals’ ability
to gather and share important information. Reduced edu-
cational achievement may affect a patient’s ability to under-
stand, and, in addition, to seek appropriate clarification of
doubts regarding the disease, the treatment, or its expected
outcomes [49]. Lack of knowledge can comprehensibly add
more anxiety and suffering to the difficulty of living with a
disease with uncertain evolution and unpredictable flares.
7. Conclusion
Giving the attention that fatigue and depression may deserve
as silent burdens of disease in SLE, we may be preventing a
deleterious progression of a disease and, thus, diminishing
the costs recently estimated in Sweden, where a total of 339
patients with the mean age of 55 years were analyzed. The
mean Health Related Quality of Life (HRQoL) measured
through the five-item EQ-5D instrument was 0.64, and total
costs were estimated at C22,594 (direct costs C7,818; indirect
costs C14,776). Disease activity, fatigue, and corticosteroid
doses had a statistically significant impact on costs and
HRQoL. This study demonstrates that Swedish patients with
SLE have low HRQoL and incur high societal costs that are
both associated with and most likely driven by disease activ-
ity, fatigue, and corticosteroid use [3].
The objective measure of costs has, like molecular and
genetic progress, become a carefully “listened to” burden of
health care and chronic disease.
We wish to conclude by returning to our starting refer-
ence to theGlobal Burden ofDisease study, referencing one of
their interpretations: “Prevalences of the most common causes
of YLDs such as mental and behavioural disorders and mus-
culoskeletal disorders have not decreased. Health systems will
need to address the needs of the rising numbers of individuals
with a range of disorders that largely cause disability but not
mortality”—such as SLE [1].
The health system will work well proportionally to the
attention and time clinicians can give to one patient.We hope
this study of SLE as a model of all modern chronic diseases,
with all its limitations as a cross-sectional study and its small
numbers, will nevertheless help clinicians and patients to
become aware of the importance of the weight of their silent
burden in the global burden ofmodern disease, where “health
is about more than avoiding death” [1].
Identifying silent burdens in SLE is essential at all times to
the care and follow-up of disease progression.
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